Comment on: Lazo et al. NH2-Terminal Pro–Brain Natriuretic Peptide and Risk of Diabetes. Diabetes 2013;62:3189–3193

  1. Andreas L. Birkenfeld3
  1. 1Institute of Metabolic and Cardiovascular Diseases, Paul Sabatier University, Toulouse, France
  2. 2Institute of Clinical Pharmacology, Hannover Medical School, Hannover, Germany
  3. 3Department of Endocrinology, Diabetes and Nutrition, Charité University School of Medicine, Berlin, Germany
  1. Corresponding author: Andreas L. Birkenfeld, andreas.birkenfeld{at}charite.de.

Lazo et al. (1) reported that plasma NH2-terminal pro–brain natriuretic peptide (NT-proBNP) levels, a cleavage product of brain natriuretic peptide (BNP), are inversely associated with diabetes risk in ∼7,800 healthy patients over a period of 12 years. In line with this, genetic evidence suggests a protective effect of BNP on diabetes risk (2). So far, mechanistic insight is lacking on how natriuretic peptides (NPs) …

| Table of Contents
OPEN ACCESS ARTICLE